NRx Pharmaceuticals Inc. (NRXP)
NASDAQ: NRXP
· Real-Time Price · USD
2.68
0.09 (3.47%)
At close: May 29, 2025, 3:59 PM
2.73
1.87%
After-hours: May 29, 2025, 07:57 PM EDT
3.47% (1D)
| Bid | 1.92 |
| Market Cap | 46.34M |
| Revenue (ttm) | 4K |
| Net Income (ttm) | -24.11M |
| EPS (ttm) | -1.96 |
| PE Ratio (ttm) | -1.37 |
| Forward PE | 3.69 |
| Analyst | Buy |
| Ask | 3.26 |
| Volume | 213,049 |
| Avg. Volume (20D) | 227,318 |
| Open | 2.63 |
| Previous Close | 2.59 |
| Day's Range | 2.51 - 2.72 |
| 52-Week Range | 1.10 - 6.01 |
| Beta | 1.45 |
About NRXP
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol NRXP
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for NRXP stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts4 months ago
+24.56%
NRx Pharmaceuticals shares are trading higher afte...
Unlock content with
Pro Subscription
4 months ago
+30.48%
NRX Pharmaceuticals shares are trading higher after the company announced it will acquire Dura Medical with HOPE Therapeutics. Additionally, the company signed a binding term sheet with HOPE with $27 million to fund further acquisitions and pharmaceutical operations.
2 months ago · seekingalpha.com
NRx Pharmaceuticals, Inc. (NRXP) Q4 2024 Earnings Call TranscriptNRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q4 2024 Earnings Conference Call March 17, 2025 8:30 AM ET Company Participants Matthew Duffy - Chief Business Officer Jonathan Javitt - Founder, Chairman and ...
